LTR Pharma Ltd
LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company.
The business
LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is developing and commercializing therapies that address significant unmet medical needs. The Company is focused on improving men’s health through clinical development and commercialization of nasal spray treatments for erectile dysfunction. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. The Company is also advancing OROFLOW, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) - a debilitating group of conditions affecting swallowing function. The Company's subsidiary is LTR Pharma Inc.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
LTR Pharma Reports 93% SPONTAN Response in Real-World ED Cohort
LTR Pharma reports 93% real-world ED response to SPONTAN in treatment-experienced men, largest cohort to date, fueling ROXUS US plans.
LTR Pharma Executes US Commercialisation Agreement with Shed DTC Platform
LTR Pharma inks US ROXUS deal with Shed; targets 150k units in year one via Mavrox telehealth—fast-acting 10-min onset.
The Weekly Finger: On Green and Gold, and Oil and Gold
Oil inventories near lows despite Iran peace chatter; gold and oil diverge on the energy complex. Small Caps weekly market wrap on ASX stocks.
LTR Pharma Signs Binding US Telehealth Term Sheet For ROXUS
LTR Pharma signs binding US telehealth term sheet with Shed Holdings for ROXUS via Mavrox; Definitive Agreements in 60 days to kickstart US commercialization.
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.